Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04624490 · ClinicalTrials.gov registry record · Phase 1

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

A Phase 1 study of Asthma and Cystic Fibrosis, sponsored by Mario Castro, MD, MPH.

Recruiting
Registry status
Phase 1
Development phase
260
Enrollment target
1
Study location

NCT04624490 is a Phase 1 study of Asthma and Cystic Fibrosis that is actively recruiting participants, run by Mario Castro, MD, MPH. The registered enrollment target is 260 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04624490, a Phase 1 study of Asthma and Cystic Fibrosis, is actively recruiting participants, sponsored by Mario Castro, MD, MPH.

RECRUITING
Registry status
Phase 1
Development phase
260 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.

Interventions

  • DRUG Hyperpolarized Xe129

Study Locations (1)

Kansas

  • University of Kansas Medical Center - Kansas City

Trial Details

FieldValue
Enrollment Target 260 participants
Start Date 2020-11-02
Est. Completion 2026-10-26
Phase Phase 1

Sponsor

Mario Castro, MD, MPH

1 total trials

What the Registry Record Tells You About NCT04624490

The ClinicalTrials.gov registry entry for NCT04624490 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (83% lower). The listed sponsor is Mario Castro, MD, MPH, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Hyperpolarized Xe129 is the first listed.

NCT04624490 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.

Frequently Asked Questions

What is clinical trial NCT04624490 about?

NCT04624490 is a clinical study titled "Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease". The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.

What is the current status of trial NCT04624490?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 260 participants. The study started on 2020-11-02. Estimated completion is 2026-10-26.

What conditions does trial NCT04624490 study?

This clinical trial studies the following conditions: Asthma, Cystic Fibrosis, COPD, Pulmonary Hypertension, Interstitial Lung Disease.

What interventions are being tested in trial NCT04624490?

The interventions under investigation include: Hyperpolarized Xe129 (DRUG).

Who is sponsoring clinical trial NCT04624490?

This trial is sponsored by Mario Castro, MD, MPH, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04624490 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.